Table. 1 Clinical and laboratory characteristics of treatment naïve, de novo CMML patients that underwent monocyte partitioning by flow cytometry
Sr. No | Age in years | Gender | 2016 WHO diagnosis | Blood counts at the time of flow cytometry | Genotype | Monocyte partitioning on flow cytometry | Autoimmune disease | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
WBC | AMC | % | Cytogenetics | Molecular genetics | MO1 | MO2 | MO3 | |||||
1 | 61 | Male | CMML-1 | 15.3 | 7.3 | 47 | 46,XY [20] | CBL, TET2, ZRSR2 | 78.4 | 21.4 | 0.2 | Hashimoto thyroiditis with severe hypothyroidism |
2 | 81 | Male | CMML-1 | 35.5 | 11.7 | 33 | 46,XY,del(20)(q11.2q13.3) [3]/46,XY [17] | ASXL1, BRAF, JAK2, SRSF2, TET2 | 84.6 | 15 | 0.2 | No |
3 | 78 | Female | CMML-1 | 7.3 | 2.9 | 40 | 46,XX [20] | ASXL1, CBL, TET2 | 88.3 | 10.4 | 1.2 | Relapsing polychondritisa |
4 | 62 | Female | CMML-1 | 18.9 | 3 | 16 | 46,XX [20] | CBL, TET2 | 90.7 | 8.2 | 0.9 | No |
5 | 49 | Male | CMML-0 | 16.5 | 3.3 | 20 | 46,XY [20] | ASXL1, CBL, IDH2, SRSF2 | 62.3 | 36.2 | 1.4 | No |
6 | 76 | Male | CMML-0 | 16.4 | 7.7 | 46 | 46,XY,del(13)(q12q22) [18]/46,XY [2] | NRAS, SRSF2, TET2 | 94.3 | 4.7 | 0.8 | No |
7 | 76 | Male | CMML-1 | 19.3 | 4.6 | 24 | 46,XY [20] | N/A | 94.8 | 3.6 | 1.5 | No |
8 | 72 | Female | CMML-2 | 4.7 | 1.4 | 30 | 46,XX,del(5)(q31q35)[14]/47,sl, +21 [3]/46,XX [3] | None | 95.2 | 4.1 | 0.66 | No |
9 | 80 | Male | CMML-1 | 9 | 4.6 | 51 | 45,X,-Y [20] | NRAS, SRSF2, TET2 | 95.6 | 4.7 | 0.1 | No |
10 | 71 | Male | CMML-1 | 12.7 | 3 | 24 | 46,XY [20] | N/A | 96.1 | 1.8 | 2 | No |
11 | 78 | Male | CMML-0 | 7.3 | 3.2 | 44 | 46,XY [20] | SRSF2, TET2 | 96.5 | 3.1 | 0.3 | No |
12 | 70 | Male | CMML-1 | 5.9 | 1.5 | 25 | 46,XY [20] | ASXL1, CBL, NRAS, TET2, U2AF1 | 97 | 2.9 | 0.1 | No |
13 | 65 | Male | CMML-0 | 9 | 1.5 | 17 | 46,XY [20] | SRSF2, TET2 | 97.7 | 1 | 1.2 | No |
14 | 73 | Female | CMML-1 | 5.9 | 1.5 | 25 | N/A | TET2, PHF6 | 98 | 1.8 | 0.1 | No |
15 | 61 | Male | CMML-1 | 4.2 | 1.9 | 45 | 46,XY [20] | SRSF2, TET2 | 98 | 1.2 | 0.8 | No |
16 | 72 | Male | CMML-1 | 4.1 | 1.5 | 37 | 46,XY [20] | N/A | 98.6 | 1 | 0.4 | No |
17 | 65 | Male | CMML-1 | 8.1 | 1.6 | 20 | 46,XY [20] | ASXL1, BCOR, NRAS, RUNX1, SRSF2 | 98.6 | 1.2 | 0.2 | No |
18 | 67 | Male | CMML-1 | 15.9 | 1.7 | 11 | 46,XX [20] | ASXL1, PHF6, RUNX1, SRSF2 | 98.8 | 1.1 | 0.1 | No |
19 | 77 | Male | CMML-2 | 32.4 | 10 | 31 | 46,XY [20] | ASXL1, SRSF2, TET2 | 99.1 | 0.8 | 0.1 | No |
20 | 83 | Female | CMML-2 | 22.1 | 4.8 | 22 | 46,XX [20] | ASXL1, BCOR, NRAS, RUNX1, SRSF2 | 99.5 | 0.3 | 0.2 | No |
